Jessica Donington, Xiaohan Hu, Su Zhang, Yan Song, Ashwini Arunachalam, Diana Chirovsky, Chi Gao, Ari Lerner, Anya Jiang, James Signorovitch, Ayman Samkari
BACKGROUND: Novel neoadjuvant chemoimmunotherapy treatments are being investigated for locally advanced non-small-cell lung cancer (NSCLC), but real-world outcomes for neoadjuvant treatments are poorly understood. This study examined neoadjuvant treatment patterns, real-world event-free survival (rwEFS) and overall survival (OS) in patients with resected, stage II-III NSCLC in the United States (US). METHODS: This retrospective study identified patients in the SEER-Medicare database (2007-2019) with newly diagnosed stage II, IIIA, and IIIB (N2) NSCLC (AJCC 8th edition) treated with neoadjuvant chemo/chemoradiotherapy and resection (index date: neoadjuvant therapy initiation)...
March 22, 2024: Clinical Lung Cancer